浙江仙琚制药股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局核准签发的关于黄体酮软胶囊的《药品注册证书》（证书编号：2025S01275、 2025S01276），公司黄体酮软胶囊被批准注册。现将相关情况公告如下： 申请内容：境内生产药品注册上市许可。 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品的其他相关情况 黄体酮软胶囊，规格为0.1g和0.2g，参比制剂为原研进口的黄体酮软胶囊， 商品名：安琪坦®（Utrogestan®）。该参比制剂由比利时Besins Healthcare开发， 0.1g规格于1981年9月在比利时批准上市，0.2g规格于2006年1月在比利时批准上 市。1992年10月，安琪坦®0.1g规格在中国获批进口，2013年5月，安琪坦®0.2g 规格在中国获批进口。黄体酮软胶囊的适应症为用于黄体缺乏引起的机能障碍， 有助于妊娠。Besins Healthcare的黄体酮软胶囊已在荷兰、法国、英国、瑞士、 1 证券代码：002332 证券简称：仙琚制药 公告编号：2025-026 浙江仙琚制 ...

Core Viewpoint - Zhejiang Xianju Pharmaceutical Co., Ltd. has announced its 2024 annual profit distribution plan, which includes a cash dividend of RMB 3.00 per 10 shares for all shareholders, approved at the shareholders' meeting on May 15, 2025 [1][2]. Summary by Sections Shareholder Meeting Approval - The profit distribution plan was approved at the 2025 annual shareholders' meeting, with a total share capital of 989,204,866 shares as of December 31, 2024 [1]. Dividend Distribution Details - The company will distribute a cash dividend of RMB 3.00 per 10 shares (before tax) to all shareholders. For specific categories of investors, the net dividend will be RMB 2.70 per 10 shares after tax deductions [1]. - Different tax rates apply for various types of shareholders, with specific provisions for those holding shares before and after the initial public offering [1]. Key Dates - The record date for the dividend distribution is set for May 27, 2025, and the ex-dividend date is May 28, 2025 [1]. Dividend Payment Method - The cash dividends will be directly credited to the shareholders' accounts through their securities companies or other custodial institutions [2]. Contact Information - For inquiries, shareholders can contact the company at its office in Zhejiang Province, with a designated contact person and phone number provided [2].

股票代码：002332 股票简称：仙琚制药 公告编号：2025-025 浙江仙琚制药股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江仙琚制药股份有限公司（以下简称"公司"或"本公司"）2024 年年 度权益分派方案已获 2025 年 5 月 15 日召开的公司 2024 年年度股东大会审议通 过，现将权益分派事宜公告如下： 3、本次实施的利润分配方案与公司 2024 年度股东大会审议通过的分配方 案一致。 4、本次实施的利润分配方案距公司 2024 年度股东大会审议通过的时间未 超过两个月。 二、本次权益分派方案 本公司 2024 年年度权益分派方案为：以公司现有总股本 989,204,866 股为 基数，向全体股东每 10 股派发现金红利人民币 3.00 元（含税；扣税后，通过 深股通持有股份的香港市场投资者、QFII、RQFII 以及持有首发前限售股的个 人和证券投资基金每 10 股派 2.70 元；持有首发后限售股、股权激励限售股及 无限售流通股的个人股息红利税实行差别化税率征收，本公司暂不扣缴个人所 ...

Financial Performance - In 2024, the company achieved a revenue of CNY 4.0 billion, a year-on-year decline of 2.98%. The net profit attributable to shareholders was CNY 397 million, down 29.46% year-on-year [3] - In Q1 2025, the company reported a revenue of CNY 1.01 billion, a decrease of 2.86% year-on-year, with a net profit of CNY 144 million, down 4.7% year-on-year [3] - The formulation business generated CNY 2.42 billion in revenue in 2024, a growth of 6.0%, while the raw material business revenue was CNY 1.55 billion, down 13.4% [3] Product Performance - In Q1 2025, the sales revenue of the formulation segment was CNY 535 million, a decline of 6.6% [4] - Key product sales by therapeutic area included: - Gynecology and family planning: CNY 100 million, down 20% - Anesthesia and muscle relaxants: CNY 36 million, up 20% - Respiratory products: CNY 210 million, up 16% - Dermatology products: CNY 55 million, up 8% - Generic drugs: CNY 116 million, down 28% [4] R&D and Innovation - The company has established a comprehensive R&D system, increasing R&D investment from CNY 80 million in 2015 to CNY 265 million in 2024, with a R&D intensity rising from 3.5% to 6.6% [6][7] - New drug applications include: - Omalizumab sodium: submitted for approval in September 2024 - Improved new drug CZ1S: entered Phase III clinical trials in February 2025 [5] - The company is focusing on high-barrier complex formulations and has multiple key R&D projects in this area [5] Market Strategy - The company is implementing a "five-in-one" strategy for internationalization, focusing on macroeconomic conditions, market demand, entry barriers, competitive landscape, and its own advantages [11] - The company anticipates growth in foreign sales despite price fluctuations, aiming to expand market share and sales of new products [12] - The sales strategy is divided into three phases: stabilize, expand, and innovate, with a focus on maintaining market presence and exploring new fields [13] Future Outlook - The company plans to enhance its product lines in the steroid hormone sector, emphasizing long-term value creation and sustainable development [9][10] - The respiratory product, Mometasone nasal spray, is expected to be a significant revenue source, with continued growth anticipated in the coming years [8] - The company aims to strengthen its supply chain by extending upstream to optimize costs and enhance market competitiveness [17]

股票代码：002332 股票简称：仙琚制药 公告编号：2025-024 浙江仙琚制药股份有限公司 2024年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会不涉及变更前次股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： 现场会议召开时间为：2025年5月15日下午14：30 网络投票时间为：2025年5月15日。其中，通过深圳证券交易所交易系统进行 网络投票时间为：2025年5月15日9:15-9:25，9:30-11:30 和 13:00-15:00；通过深 圳证券交易所互联网投票系统开始投票的时间为：2025年5月15日9:15- 15:00。 2、现场会议召开地点：浙江仙琚制药股份有限公司会议室； 3、会议召集人：公司董事会； （二）会议的出席情况 1、出席会议股东总体情况 4、会议方式：本次股东大会采取现场投票和网络投票相结合的方式； 5、股权登记日：2025年5月12日； 6、现场会议主持人：公司董事长张宇松先生； 本次会议 ...

上海市锦天城律师事务所 关于浙江仙琚制药股份有限公司 2024 年年度股东大会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 楼 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于浙江仙琚制药股份有限公司 2024 年年度股东大会的 法律意见书 致：浙江仙琚制药股份有限公司 （二）本次股东大会的召开 本次股东大会现场会议于 2025 年 5 月 15 日 14:30 在浙江省仙居县福应街道 现代工业集聚区丰溪西路 15 号浙江仙琚制药股份有限公司五楼会议室如期召开。 本次股东大会采取现场投票和网络投票相结合的方式召开。本次股东大会通 过深圳证券交易所系统进行网络投票的具体时间为 2025 年 5 月 15 日 9:15-9:25， 9:30-11:30 和 13:00-15:00；通过深圳证券交易所互联网投票系统投票的具体时间 为 2025 年 5 月 15 日 9:15-15:00。 上海市锦天城律师事务所（以下简称"本所"）接受浙江仙琚制药股份有限 公司（以下简称"公司" ...

Core Viewpoint - Three pharmaceutical companies, Xianju Pharmaceutical, Tianjin Pharmaceutical, and Lianhuan Pharmaceutical, have been penalized for monopolistic practices related to the raw material dexamethasone sodium phosphate, with total fines amounting to approximately 325 million yuan [1][2][3]. Group 1: Penalties and Financial Impact - Xianju Pharmaceutical was fined a total of approximately 195 million yuan, which includes the confiscation of illegal gains of 23.74 million yuan and a fine of about 172 million yuan based on 8% of its 2023 sales [2][5]. - Tianjin Pharmaceutical faced penalties totaling approximately 69.19 million yuan, including the confiscation of illegal gains of 42.76 million yuan and a reduced fine of about 13.2 million yuan after an 80% reduction [3][5]. - Lianhuan Pharmaceutical was fined approximately 61.04 million yuan, which includes the confiscation of illegal gains of 17.89 million yuan and a reduced fine of about 61.63 million yuan after a 30% reduction [3][5]. Group 2: Profitability Impact - The fines significantly impact the profitability of the companies, with Tianjin Pharmaceutical's penalties representing 2.15% of its recent audited revenue and 51.85% of its net profit attributable to shareholders [5]. - For Xianju Pharmaceutical, the total fine of 195 million yuan accounts for 4.87% of its projected 2024 revenue of 4 billion yuan and 49.17% of its net profit of 397 million yuan [5]. - Lianhuan Pharmaceutical's proposed fines represent 72.53% of its net profit of 84 million yuan for the previous year [5]. Group 3: Recurrence of Violations - Tianjin Pharmaceutical has been penalized for monopolistic behavior for the fourth time in four years, with cumulative fines exceeding 170 million yuan [6][7].

Core Viewpoint - Four companies engaged in a price-fixing conspiracy for dexamethasone phosphate raw materials, leading to significant price increases and resulting in administrative penalties exceeding 350 million yuan [1][5][15] Group 1: Companies Involved - The companies involved in the price-fixing conspiracy are Tianjin Pharmaceutical Industry Co., Ltd. (津药药业), Xianju Pharmaceutical Co., Ltd. (仙琚制药), Lianhuan Pharmaceutical Co., Ltd. (联环药业), and Xi'an Guokang Ruijin Pharmaceutical Co., Ltd. (西安国康瑞金) [1][5][14] - The main organizer of the conspiracy was identified as an individual named Guo, who facilitated communication and coordination among the companies [5][6] Group 2: Price Changes - The price of dexamethasone phosphate raw materials increased from several thousand yuan per kilogram to over ten thousand yuan, with some companies raising prices as high as 38,000 yuan per kilogram [1][10][14] - Specific price increases included Tianjin Pharmaceutical raising prices from a maximum of 9,000 yuan to 13,800 yuan per kilogram, and Xi'an Guokang Ruijin increasing prices from 7,900 yuan to between 10,000 and 38,000 yuan per kilogram [10][14] Group 3: Administrative Penalties - The total penalties imposed on the companies amounted to over 350 million yuan, with Tianjin Pharmaceutical fined 69.19 million yuan, Xianju Pharmaceutical fined 195.3 million yuan, and Xi'an Guokang Ruijin fined 28.78 million yuan [1][12][13] - Lianhuan Pharmaceutical is expected to face a fine of 61.04 million yuan, with a proposed reduction of 30% due to its cooperation during the investigation [1][11] Group 4: Cooperation and Leniency - Tianjin Pharmaceutical was the first to submit a leniency application, providing crucial evidence and reporting the details of the price-fixing agreement, which led to an 80% reduction in its fine [2][11] - In contrast, Xianju Pharmaceutical and Xi'an Guokang Ruijin did not submit leniency applications, resulting in no reductions in their fines [2][12][14]

Group 1 - The core issue involves Xianju Pharmaceutical (002332) receiving an administrative penalty from the Tianjin Municipal Market Supervision Administration for engaging in a monopoly agreement to fix the price of Dexamethasone Phosphate Sodium raw materials, violating Article 17(1) of the Anti-Monopoly Law of the People's Republic of China [1] - The company is ordered to cease illegal activities and faces a total penalty of RMB 195,296,912.22, which includes the confiscation of illegal gains amounting to RMB 23,746,680.00 and a fine of RMB 171,550,232.22, equivalent to 8% of its 2023 sales [1] - Other companies involved in the same matter, including Tianyao Pharmaceutical (600488.SH) and Lianhuan Pharmaceutical (600513.SH), were also penalized, with fines of RMB 69,192,400 and RMB 61,038,200 respectively [3]

今日焦点中国中车：近期签订合计547.4亿元重大合同 中国中车公告称，公司及下属企业于近期（主要为2024年12月至2025年5月）签订了若干项重大合同， 合计金额约547.4亿元人民币。主要合同包括城市轨道车辆、设备销售及维保合同，动车组销售合同， 动车组高级修合同，风电设备销售合同和储能设备销售合同，机车销售合同以及货车修理合同。上述合 同总金额约占公司中国会计准则下2024年营业收入的22.2%。 阳光诺和：拟购买朗研生命100%股权，股票明日复牌 南方财经5月12日电，阳光诺和(688621.SH)公告称，公司拟通过发行股份及可转换公司债券购买资产并 募集配套资金，购买利虔、朗颐投资等38名朗研生命股东持有的朗研生命100%股权。并向不超过35名 特定投资者发行股份募集配套资金。朗研生命专注于高端化学药及原料药的研发、生产和销售，并对外 提供药品生产服务，在高端化学药、原料药等领域深耕多年，已经形成了较为成熟的医药生产体系。公 司股票将于5月13日开市起复牌。 沃尔核材：筹划发行H股股票并申请在香港联交所主板上市 沃尔核材公告称，公司拟发行H股股票并申请在香港联交所主板挂牌上市，以推进国际化战略，提升 ...